MICHELLE MORTON: Open Payments
NPI 1417423765 · DALLAS, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,725 in 76 payments from 16 companies in 2025. Trend: 2023 $1,373 · 2024 $2,556 · 2025 $2,725
Food & beverage: $2,088Speaker / faculty: $638
| Company | Payments | Amount |
|---|---|---|
| Ipsen Biopharmaceuticals, Inc | 7 | $761 |
| Madrigal Pharmaceuticals | 12 | $527 |
| Gilead Sciences, Inc. | 19 | $478 |
| ABBVIE INC. | 13 | $227 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 12 | $226 |
| Novo Nordisk Inc | 1 | $122 |
| E.R. Squibb & Sons, L.L.C. | 1 | $121 |
| Eisai Inc. | 3 | $80 |
| Alkermes, Inc. | 1 | $31 |
| Boston Scientific Corporation | 1 | $29 |
Products named: IQIRVO, REZDIFFRA, MAVYRET, XIFAXAN, Lenvima, VIVITROL, Resolution 360 Clip, CUVRIOR.
Industry payments across TX — which companies pay providers there.
